~ Buy the APLENZIN (bupropion hydrobromide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR APLENZIN

All Clinical Trials for APLENZIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	Johns Hopkins University	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	National Institute on Drug Abuse (NIDA)	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	SRI International	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	University of Bristol	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	Stanford University	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT02129751 ↗	Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder	Not yet recruiting	Bausch Health Americas, Inc.	Phase 4	2021-11-01	Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety

Clinical Trial Conditions for APLENZIN

Condition Name

Condition Name for APLENZIN
Intervention	Trials
Major Depressive Disorder	1
Smoking	1

Condition MeSH

Condition MeSH for APLENZIN
Intervention	Trials
Disease	1
Depressive Disorder, Major	1
Depressive Disorder	1
Depression	1

Clinical Trial Locations for APLENZIN

Trials by Country

Trials by Country for APLENZIN
Location	Trials
United States	3

Trials by US State

Trials by US State for APLENZIN
Location	Trials
New Jersey	1
Washington	1
California	1

Clinical Trial Progress for APLENZIN

Clinical Trial Phase

Clinical Trial Phase for APLENZIN
Clinical Trial Phase	Trials
Phase 4	2

Clinical Trial Status

Clinical Trial Status for APLENZIN
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for APLENZIN

Sponsor Name

Sponsor Name for APLENZIN
Sponsor	Trials
University of Bristol	1
Stanford University	1
Bausch Health Americas, Inc.	1

Sponsor Type

Sponsor Type for APLENZIN
Sponsor	Trials
Industry	3
Other	3
NIH	1